Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 USD | +1.30% | -12.03% | +87.20% |
Apr. 16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
Apr. 16 | Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study | CI |
Chart calendar Lexaria Bioscience Corp.
Past events on Lexaria Bioscience Corp.
2024-04-09 10:30 am | LD Micro Invitational Conference |
2023-10-10 04:00 pm | Extraordinary Shareholders Meeting |
2023-09-11 | H.C. Wainwright Global Investment Conference |
2023-05-30 | Investor Meeting |
2023-05-09 04:00 pm | Annual General Meeting |
2023-04-14 06:03 pm | Q2 2023 Earnings Release |
2023-01-17 09:54 pm | Q1 2023 Earnings Release |
2022-10-24 | LD Micro Main Event XV |
2022-06-06 | LD Micro Invitational XII Conference |
2022-05-31 04:00 pm | Annual General Meeting |
2022-04-10 | Interim 2022 Earnings Release |
2022-01-13 | Q1 2022 Earnings Release |
2021-12-08 09:30 am | Benzinga Global Small Cap Conference |
2021-10-27 | Partnership Opportunities in Drug Delivery |
2021-09-13 07:00 am | H.C. Wainwright Global Investment Conference |
2021-07-15 06:46 pm | Q3 2021 Earnings Release |
2021-06-28 04:00 pm | Annual General Meeting |
2021-06-24 11:00 am | Life Sciences Investor Forum |
2021-05-13 03:30 pm | Benzinga Global Small Cap Conference |
2021-03-24 09:45 am | Benzinga Biotech Small Cap Conference |
Annual results
Fiscal Period | August | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,22 0,20 11.31% | 0,00 | 0,72 0,92 -21.11% | 0,26 0,34 -24.66% | 0,23 0,32 -28.75% | 0,48 |
EBITDA Million USD | Released Forecast Spread | -3,80 -3,30 -15.01% | 0,00 | -5,58 -5,66 1.51% | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBIT Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 | 0,00 0,00 - | -7,38 -7,18 -2.91% | -6,53 -6,56 0.46% | -6,25 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 | 0,00 0,00 - | -7,38 -7,18 -2.91% | -6,71 -6,54 -2.58% | -6,28 |
Net income Million USD | Released Forecast Spread | 0,00 0,00 - | -3,93 | 0,00 0,00 - | -7,38 -7,18 -2.91% | -6,66 -6,54 -1.85% | -6,28 |
EPS USD | Released Forecast Spread | 0,00 0,00 - | -1,50 | 0,00 0,00 - | -1,24 -1,21 -2.48% | -1,01 -1,00 -1.51% | -0,54 |
Announcement Date | 14/11/19 | 14/10/20 | 29/11/21 | 28/11/22 | 20/11/23 | - |
Quarterly results
Fiscal Period | August | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,03 0,15 -79.57% | 0,10 0,12 -16.9% | 0,11 0,20 -43% | 0,09 0,08 16.44% | 0,00 0,09 -103.92% | 0,15 0,00 - | 0,15 0,00 - | 0,00 | 0,00 | |
EBIT Million USD | Released Forecast Spread | -1,45 -1,28 -13.35% | -2,42 -1,71 -41.42% | -1,51 -1,31 -15.95% | -2,38 -1,53 -56.3% | -1,07 -1,10 2.73% | -1,14 -1,06 -7.16% | -0,67 -1,18 43.44% | -1,91 | -1,97 | |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -1,45 -1,28 -13.35% | -2,42 -1,71 -41.42% | -1,51 -1,31 -15.95% | -2,38 -1,52 -57.02% | -1,25 -1,10 -13.86% | -1,19 -1,06 -11.48% | -0,65 -1,18 44.73% | -1,91 | -1,97 | |
Net income Million USD | Released Forecast Spread | -1,43 -1,28 -11.56% | -2,38 -1,71 -39.35% | -1,51 -1,31 -15.95% | -1,30 | -2,37 -1,52 -56.23% | -1,24 -1,10 -12.97% | -1,18 -1,06 -10.94% | -0,65 -1,18 45% | -1,91 | -1,97 |
EPS USD | Released Forecast Spread | -0,25 -0,21 -19.05% | -0,41 -0,28 -46.43% | -0,24 -0,21 -14.29% | -0,22 | -0,37 -0,25 -48% | -0,12 -0,14 11.11% | -0,13 -0,11 -18.18% | -0,06 -0,10 40% | -0,13 | -0,12 |
Announcement Date | 11/04/22 | 14/07/22 | 28/11/22 | 14/04/23 | 14/07/23 | 20/11/23 | 12/01/24 | 09/04/24 | - | - |
Past sector events for Lexaria Bioscience Corp.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LEXX Stock
- Calendar Lexaria Bioscience Corp.